GENERIC ADDERALL XR
ER CNS stimulant
Approved Dec 2019
Got API thru end of calendar 2020
Got Quota to deal with US shortage
Launched Mar 2020
(((( $1.5 Billion market )))) per IQVIA
Milestone and revenues to follow
$$$$ This generics competition are ALL “Authorized “ generics which pay royalties to the branded. Elite does not have to pay those royalties which gives Elite an edge on the competition $$$$$
Elite has officially become * Cash Flow Positive * with The Monster Launched (Adderall XR)
Monster Revenues slows/halts dilution
Finances all future R&D
Removes all going concerns
Pays for trials for unique ADF that is cheaper than those with Naltrexone
Pays for Elite’s wholly owned Godzilla - an undisclosed CNS stimulant with a $2.2 Billion Market per IQVIA
Massive organic growth
Generic Adderall XR is jointly owned and the second product approval for Elite and Mikah Pharma LLC collaboration. Elite will manufacture and package the product on a cost-plus basis. Lannett Company, Inc. will be the exclusive U.S. distributor.
"We are pleased to have received approval of this second product” said Nasrat Hakim, President and CEO of Elite and Mikah.
The Launch of this product was Elite’s top priority."
Quote Nasrat: .
“ This is an outstanding product for us once we get an approval because we will be the fifth in this arena, and even if there were more people than that and we've got just 10% of that market, that's $160 million, a $160 million in revenues will do wonders to Elite stock. Even if we cut it in half between us and SunGen and you take out the actual cost which is another half and walk away with only $40 million, that will take our market cap from 80 million which is today to $800 million with one product only."
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate, Extended- Release Capsules
“Game Changer”
ELTP